360 related articles for article (PubMed ID: 35471832)
1. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers.
Alese OB; Cook N; Ortega-Franco A; Ulanja MB; Tan L; Tie J
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-20. PubMed ID: 35471832
[TBL] [Abstract][Full Text] [Related]
2. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
3. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
4. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
Barlebo Ahlborn L; Østrup O
APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
[TBL] [Abstract][Full Text] [Related]
5. Applications of Liquid Biopsy for Surgical Patients With Cancer: A Review.
Mahuron KM; Fong Y
JAMA Surg; 2024 Jan; 159(1):96-103. PubMed ID: 37910091
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
Croessmann S; Park BH
Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
[TBL] [Abstract][Full Text] [Related]
7. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
[TBL] [Abstract][Full Text] [Related]
10. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies.
Ueberroth BE; Jones JC; Bekaii-Saab T
Clin Adv Hematol Oncol; 2022 Jul; 20(7):444-455. PubMed ID: 35802877
[TBL] [Abstract][Full Text] [Related]
11. Mind the target: circulating tumour DNA in gastrointestinal malignancies.
Fontana E; Ignatova E
Curr Opin Oncol; 2022 Jul; 34(4):395-402. PubMed ID: 35837709
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.
Merk C; Martling A; Lindberg J; Benhaim L; Taieb J; Lind P
Acta Oncol; 2022 Apr; 61(4):523-530. PubMed ID: 35139729
[TBL] [Abstract][Full Text] [Related]
13. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
[TBL] [Abstract][Full Text] [Related]
14. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.
Schrock AB; Pavlick D; Klempner SJ; Chung JH; Forcier B; Welsh A; Young L; Leyland-Jones B; Bordoni R; Carvajal RD; Chao J; Kurzrock R; Sicklick JK; Ross JS; Stephens PJ; Devoe C; Braiteh F; Ali SM; Miller VA
Clin Cancer Res; 2018 Apr; 24(8):1881-1890. PubMed ID: 29363525
[No Abstract] [Full Text] [Related]
15. Cell-free DNA as a post-treatment surveillance strategy: current status.
Burgener JM; Rostami A; De Carvalho DD; Bratman SV
Semin Oncol; 2017 Oct; 44(5):330-346. PubMed ID: 29580435
[TBL] [Abstract][Full Text] [Related]
16. Waiting for the "liquid revolution" in the adjuvant treatment of colon cancer patients: a review of ongoing trials.
Conca V; Ciracì P; Boccaccio C; Minelli A; Antoniotti C; Cremolini C
Cancer Treat Rev; 2024 May; 126():102735. PubMed ID: 38613871
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor DNA: current challenges for clinical utility.
Dang DK; Park BH
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
19. Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients.
Koldby KM; Mortensen MB; Detlefsen S; Pfeiffer P; Thomassen M; Kruse TA
J Gastroenterol; 2019 Feb; 54(2):108-121. PubMed ID: 30242476
[TBL] [Abstract][Full Text] [Related]
20. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer.
Bent A; Raghavan S; Dasari A; Kopetz S
Clin Colorectal Cancer; 2022 Jun; 21(2):89-95. PubMed ID: 35450837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]